EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND ROBERT F. CAREYExecutive Employment • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015, (hereinafter referred to together as the “Company”) and Robert F. Carey (hereinafter referred as to the “Executive”). The terms of this Agreement shall remain confidential until the Executive’s first day of employment with the Company (the “Date of Hire”), which will be on March 5, 2014 and which is also the effective date of this Agreement (the “Effective Date”).
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES by and between POZEN INC. and ASTRAZENECA AB November 18, 2013Collaboration and License Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
LICENSE AGREEMENT By and between AstraZeneca AB and Horizon Pharma USA, Inc. Dated as of November 22, 2013License Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into effective as of November 22, 2013 (the “Effective Date”) by and between AstraZeneca AB, a Swedish corporation (“AstraZeneca”), and Horizon Pharma USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Horizon”). AstraZeneca and Horizon are sometimes referred herein individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT By and between AstraZeneca AB and Horizon Pharma USA, Inc. Dated as of November 18, 2013Asset Purchase Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made and executed as of November 18, 2013 (the “Execution Date”), by and between AstraZeneca AB, a Swedish corporation (“AstraZeneca”), and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon”). AstraZeneca and Horizon are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
November 18, 2013 AstraZeneca AB SE-431 83 Mölndal Sweden Attn: President POZEN Inc. Chapel Hill, North Carolina 27517 Attn: President and Chief Executive OfficerHorizon Pharma, Inc. • March 13th, 2014 • Pharmaceutical preparations
Re: Acknowledgements and agreements regarding rights and responsibilities of the parties in relation to the License Agreements
EXCLUSIVE DISTRIBUTION AGREEMENT – AMENDMENT No. 2Distribution Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations
Master Manufacturing Services Agreement October 31, 2013Product Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
SUPPLY AGREEMENTSupply Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York
THIS SUPPLY AGREEMENT (“Agreement”) is made and entered into effective as of November 22, 2013 (the “Effective Date”), by and between ASTRAZENECA LP, a Delaware limited partnership (“AstraZeneca”), having offices at 1800 Concord Pike, Wilmington, Delaware 19803, and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon”), having an office at 520 Lake Cook Road, Suite 520, Deerfield, Illinois 60015. AstraZeneca and Horizon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
SECOND AMENDMENT TO LEASE (Corporate 500 Centre)Lease • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (“Second Amendment”) is made and entered into as of the 10th day of December, 2013, by and between LONG RIDGE OFFICE PORTFOLIO, L.P., a Delaware limited partnership (“Landlord”), and HORIZON PHARMA USA, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATESCollaboration and License Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Amendment”) is made by and between POZEN Inc., a Delaware corporation (“POZEN”), and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon,” and together with POZEN, the “Parties”). Reference is made to that certain Amended and Restated Collaboration and License Agreement for the United States, dated as of November 18, 2013, by and between POZEN and Horizon, as successor in interest to AstraZeneca AB (“AZ”) (the “Agreement”). All capitalized terms not herein defined shall have the meaning ascribed to them in the Agreement. This Amendment shall be effective automatically as of the Amended and Restated Effective Date.
MANUFACTURING AND SUPPLY AGREEMENT – AMENDMENT No. 2Manufacturing and Supply Agreement • March 13th, 2014 • Horizon Pharma, Inc. • Pharmaceutical preparations
